Epigenomic alterations define lethal CIMP-positive ependymomas of infancy

Nature

Volumn 506, Issue 7489, 2014, Pages 445-450

  MacK, S C ^a,b,c   Witt, H ^d,e   Piro, R M ^d   Gu, L ^d   Zuyderduyn, S ^b   Stutz A M ^d,f   Wang, X ^a,b   Gallo, M ^a   Garzia, L ^a   Zayne, K ^a   Zhang, X ^g   Ramaswamy, V ^a,b   Jager N ^d   Jones, D T W ^d   Sill, M ^d   Pugh, T J ^h   Ryzhova, M ^d   Wani, K M ⁱ   Shih, D J H ^a,b   Head, R ^a   Remke, M ^a,b   Bailey, S D ^j,k   Zichner, T ^d,f   Faria, C C ^a   Barszczyk, M ^a,b   Stark, S ^d   Seker Cin, H ^d   Hutter, S ^d   Johann, P ^d   Bender, S ^d   Hovestadt, V ^d   Tzaridis, T ^d   Dubuc, A M ^a,b   Northcott, P A ^d   Peacock, J ^a,b   Bertrand, K C ^a,b   Agnihotri, S ^a   Cavalli, F M G ^a   Clarke, I ^a   Nethery Brokx, K ^a   Creasy, C L ^l   Verma, S K ^l   Koster, J ^m   Wu, X ^a   Yao, Y ^a,b   Milde, T ^d,e   Sin Chan, P ^a   Zuccaro, J ^a   Lau, L ^a   Pereira, S ^a   Castelo Branco, P ^a   Hirst, M ^n,o   Marra, M A ^n,o   Roberts, S S ^p   Fults, D ^q   Massimi, L ^r   Cho, Y J ^s   Van Meter, T ^t   Grajkowska, W ^u   Lach, B ^v   Kulozik, A E ^d,e   Von Deimling, A ^d,e   Witt, O ^d,e   Scherer, S W ^a   Fan, X ^w,x   Muraszko, K M ^x   Kool, M ^d   Pomeroy, S L ^h   Gupta, N ^y   Phillips, J ^y   Huang, A ^a   Tabori, U ^a   Hawkins, C ^a,b   Malkin, D ^a   Kongkham, P N ^a,b,c   Weiss, W A ^y   Jabado, N ^z   Rutka, J T ^a,b,c   Bouffet, E ^a   Korbel, J O ^f   Lupien, M ^b,j,k   Aldape, K D ⁱ   Bader, G D ^b   Eils, R ^d   Lichter, P ^d   Dirks, P B ^a,b,c   Pfister, S M ^d,e   Korshunov, A ^d,w   Taylor, M D ^a,b,c   more..

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f Genome Biology   (Germany)

^g DARTMOUTH MEDICAL SCHOOL   (United States)

^h BOSTON CHILDREN S HOSPITAL   (United States)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^j PRINCESS MARGARET HOSPITAL   (Canada)

^k Department of Biochemistry Norman Institute for Cancer Research   (Canada)

^l GLAXOSMITHKLINE   (United States)

^m ACADEMIC MEDICAL CENTER   (Netherlands)

ⁿ UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^o BRITISH COLUMBIA CANCER AGENCY   (Canada)

^p UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^q UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^r FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^s STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^t Virginia Commonwealth ^*  (United States)

^u UNIVERSITY OF WARSAW   (Poland)

^v HAMILTON GENERAL HOSPITAL   (Canada)

^w UNIVERSITY OF MICHIGAN   (United States)

^x UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^y UNIVERSITY OF CALIFORNIA   (United States)

^z RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEOTIDE; POLYCOMB REPRESSIVE COMPLEX 2;

BRAIN; CHEMOTHERAPY; DRUG; GENETIC DIFFERENTIATION; GENOME; INFANT MORTALITY; METHYLATION; MUTATION; PHENOTYPE; SURVIVAL; TUMOR;

ARTICLE; CANCER PROGNOSIS; COPY NUMBER VARIATION; CPG ISLAND METHYLATOR PHENOTYPE POSITIVE EPENDYMOMA OF INFANCY; DNA METHYLATION; EPENDYMOMA; EPIGENETICS; EXOME; GENE EXPRESSION; GENE REPRESSION; GENE SEQUENCE; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; RHOMBENCEPHALON; SOMATIC MUTATION;

ANIMALS; BRAIN NEOPLASMS; CPG ISLANDS; DNA METHYLATION; EMBRYONIC STEM CELLS; EPENDYMOMA; EPIGENESIS, GENETIC; EPIGENOMICS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HISTONES; HUMANS; INFANT; MICE; MICE, INBRED NOD; MICE, SCID; MUTATION; PHENOTYPE; POLYCOMB REPRESSIVE COMPLEX 2; PROGNOSIS; RHOMBENCEPHALON; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84896739200     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature13108     Document Type: Article

References (50)

1. Taylor, M. D. et al. Radial glia cells are candidate stemcells of ependymoma. Cancer Cell 8, 323-335 (2005).
2. Merchant, T. E. et al. Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study. Lancet Oncol. 10, 258-266 (2009).
3. Bouffet, E. & Foreman, N. Chemotherapy for intracranial ependymomas. Childs Nerv. Syst. 15, 563-570 (1999).
4. Bouffet, E. et al. Survival benefit for pediatric patients with recurrent ependymoma treated with reirradiation. Int. J. Radiat. Oncol. Biol. Phys. 83, 1541-1548 (2012).
5. Johnson, R. A. et al. Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature 466, 632-636 (2010).
6. Witt, H. et al. Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell 20, 143-157 (2011).
7. Wani, K. et al. A prognostic gene expression signature in infratentorial ependymoma. Acta Neuropathol. 123, 727-738 (2012).
8. Atkinson, J. M. et al. An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. Cancer Cell 20, 384-399 (2011).
9. Jones, D. T. et al. Dissecting the genomic complexity underlyingmedulloblastoma. Nature 488, 100-105 (2012).
10. Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214-218 (2013).
11. Dees, N. D. et al. MuSiC: identifying mutational significance in cancer genomes. Genome Res. 22, 1589-1598 (2012).
12. Brennan, C. W. et al. The somatic genomic landscape of glioblastoma. Cell 155, 462-477 (2013).
13. Koboldt, D. C. et al. Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).
14. Muzny, D. M. et al. Comprehensivemolecular characterization of humancolon and rectal cancer. Nature 487, 330-337 (2012).
15. Peifer, M. et al. Integrative genomic analyses identify key somatic drivermutations of small-cell lung cancer. Nature Genetics 44, 1104-1110 (2012).
16. Zhang, J. et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 481, 157-163 (2012).
17. Hammerman, P. S. et al. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519-525 (2012).
18. Hodis,E. et al.Alandscape ofdriver mutations inmelanoma. Cell 150,251-263(2012).
19. Chapman, M.A. et al. Initial genomesequencingandanalysis ofmultiplemyeloma. Nature 471, 467-472 (2011).
20. Imielinski, M. et al. Mapping the hallmarks of lung adenocarcinomawith massively parallel sequencing. Cell 150, 1107-1120 (2012).
21. Bell, D. et al. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615 (2011).
22. Pugh, T. J. et al. The genetic landscape of high-risk neuroblastoma. Nature Genetics 45, 279-284 (2013).
23. Berger, M. F. et al. The genomic complexity of primary human prostate cancer. Nature 470, 214-220 (2011).
24. Lee, R. S. et al. A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. J. Clin. Invest. 122, 2983-2988 (2012).
25. Zhang, J. et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature 481, 329-334 (2012).
26. Northcott, P. A. et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature 488, 49-56 (2012).
27. Pugh, T. J. et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 488, 106-110 (2012).
28. Robinson, G. et al. Novel mutations target distinct subgroups ofmedulloblastoma. Nature 488, 43-48 (2012).
29. Schwartzentruber, J. et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482, 226-231 (2012).
30. Sausen,M. et al. Integrated genomic analyses identify ARID1A and ARID1B alterationsinthechildhoodcancerneuroblastoma.NatureGenet. 45,12-17(2013).
31. Wu, G. et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nature Genet. 44, 251-253 (2012).
32. Versteege, I. et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 394, 203-206 (1998).
33. Northcott,P.A. et al.Multiple recurrent genetic eventsconverge oncontrol of histone lysinemethylation inmedulloblastoma. Nature Genet. 41, 465-472 (2009).
34. Noushmehr, H. et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17, 510-522 (2010).
35. Ohm, J. E. et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes toDNA hypermethylation and heritable silencing. Nature Genet. 39, 237-242 (2007).
36. Kantarjian, H. et al. Decitabine improves patient outcomes inmyelodysplastic syndromes:results of aphase III randomizedstudy.Cancer 106,1794-1803(2006).
37. Tan, J. et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 21, 1050-1063 (2007).
38. McCabe, M. T. et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492, 108-112 (2012).
39. Turcan, S. et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483, 479-483 (2012).
40. Williams, K. et al. TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity. Nature 473, 343-348 (2011).
41. Fang, F. et al. Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci. Transl. Med. 3, 75ra25 (2011).
42. Roman-Gomez, J. et al. Lack of CpG island methylator phenotype defines a clinical subtype of T-cell acute lymphoblastic leukemia associated with good prognosis. J. Clin. Oncol. 23, 7043-7049 (2005).
43. Zouridis, H. et al. Methylation subtypes and large-scale epigenetic alterations in gastric cancer. Sci. Transl. Med. 4, 156ra140 (2012).
44. Toyota, M. et al. CpG island methylator phenotype in colorectal cancer. Proc. Natl Acad. Sci. USA 96, 8681-8686 (1999).
45. Weisenberger, D. J. et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAFmutation in colorectal cancer. Nature Genet. 38, 787-793 (2006).
46. Ben-Porath, I. et al. Anembryonic stemcell-like gene expression signature inpoorly differentiated aggressive human tumors. Nature Genet. 40, 499-507 (2008).
47. Down, T. A. et al. A Bayesian deconvolution strategy for immunoprecipitationbased DNA methylome analysis. Nature Biotechnol. 26, 779-785 (2008).
48. Lupien, M. et al. FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell 132, 958-970 (2008).
49. Hansen, K. D. et al. Increased methylation variation in epigenetic domains across cancer types. Nature Genet. 43, 768-775 (2011).
50. Gallo, M. et al. A tumorigenic MLL-homeobox network in human glioblastoma stem cells. Cancer Res. 73, 417-427 (2013).